Effects of Saxagliptin on Adipose Tissue Inflammation in Humans
Status:
Completed
Trial end date:
2019-10-12
Target enrollment:
Participant gender:
Summary
In this research study, Investigators will be comparing the effects of a medication
Saxagliptin versus placebo (a similar looking pill that contains no medication) on
inflammation in the body.
Research Hypothesis DPP-4 inhibition by saxagliptin (ONGLYZA™) reduces adipose tissue
inflammation in obese individuals and this is characterized by decreases in a) reactive
oxygen species (ROS) production, b) toll-like receptors (TLR) and NF-kappa B pathway
activation, c) expression of pro-inflammatory genes, d) macrophage infiltration, and e)
secretion of pro-inflammatory factors.